ANI Pharmaceuticals/$ANIP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ANI Pharmaceuticals
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Ticker
$ANIP
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
897
ISIN
US00182C1036
Website
ANIP Metrics
BasicAdvanced
$1.3B
-
-$1.15
0.56
-
Price and volume
Market cap
$1.3B
Beta
0.56
52-week high
$77.00
52-week low
$52.50
Average daily volume
315K
Financial strength
Current ratio
2.657
Quick ratio
1.861
Long term debt to equity
139.502
Total debt to equity
142.026
Interest coverage (TTM)
0.45%
Profitability
EBITDA (TTM)
90.501
Gross margin (TTM)
59.34%
Net profit margin (TTM)
-3.12%
Operating margin (TTM)
2.16%
Effective tax rate (TTM)
23.63%
Revenue per employee (TTM)
$750,000
Management effectiveness
Return on assets (TTM)
0.82%
Return on equity (TTM)
-4.57%
Valuation
Price to revenue (TTM)
1.898
Price to book
3.15
Price to tangible book (TTM)
-7.3
Price to free cash flow (TTM)
27.288
Free cash flow yield (TTM)
3.66%
Free cash flow per share (TTM)
241.17%
Growth
Revenue change (TTM)
30.26%
Earnings per share change (TTM)
-171.33%
3-year revenue growth (CAGR)
43.93%
10-year revenue growth (CAGR)
26.57%
3-year earnings per share growth (CAGR)
-37.19%
10-year earnings per share growth (CAGR)
-7.78%
What the Analysts think about ANIP
Analyst ratings (Buy, Hold, Sell) for ANI Pharmaceuticals stock.
Bulls say / Bears say
ANI Pharmaceuticals reported record quarterly net revenues of $197.1 million in Q1 2025, a 43.4% year-over-year increase, driven by strong demand for Cortrophin Gel and Generics. (Nasdaq)
The acquisition of Alimera Sciences in September 2024 added ILUVIEN and YUTIQ to ANI's Rare Disease portfolio, contributing $27.6 million in Q4 2024 revenues and expanding the company's ophthalmology offerings. (ANI Pharmaceuticals)
HC Wainwright reiterated a 'Buy' rating for ANI Pharmaceuticals in March 2025, reflecting confidence in the company's growth prospects and financial performance. (ETF Daily News)
ANI Pharmaceuticals' Selling, General, and Administrative expenses increased by 59.4% in Q1 2025, primarily due to the Alimera acquisition, which may impact profitability. (Nasdaq)
The company's gross margin decreased from 64.2% to 62.9% in Q1 2025, indicating potential challenges in maintaining operational efficiency. (Nasdaq)
ANI Pharmaceuticals issued $275 million in convertible senior notes in August 2024, increasing its debt obligations and potential dilution for existing shareholders. (Stock Titan)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
ANIP Financial Performance
Revenues and expenses
ANIP Earnings Performance
Company profitability
ANIP News
AllArticlesVideos
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
GlobeNewsWire·2 weeks ago
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ANI Pharmaceuticals stock?
ANI Pharmaceuticals (ANIP) has a market cap of $1.3B as of June 27, 2025.
What is the P/E ratio for ANI Pharmaceuticals stock?
The price to earnings (P/E) ratio for ANI Pharmaceuticals (ANIP) stock is 0 as of June 27, 2025.
Does ANI Pharmaceuticals stock pay dividends?
No, ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next ANI Pharmaceuticals dividend payment date?
ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders.
What is the beta indicator for ANI Pharmaceuticals?
ANI Pharmaceuticals (ANIP) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.